Immunovia attends Aktiespararna Life Science

Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it will participate in the Aktiesparna Digital Temakväll Life Science investor event. President and CEO Jeff Borcherding will present the company’s commercial strategy and launch activities.

On January 26, 2026, at 19:20 CET, Immunovia will present its strategic roadmap and priorities for the commercialization of its PancreaSure test. During the presentation, President and CEO Jeff Borcherding will provide additional details regarding recent developments, including the company’s recent regulatory approval in California to offer PancreaSure commercially.

The event will be broadcasted live at Aktiespararna’s website: https://www.aktiespararna.se/aktiviteter/digital-temakvall---life-science-69344

If you have question for the company during the presentation, you may contact the event manager through Aktiespararna’s event website.

For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.